Purpose: Tolerability and completion of pembrolizumab with neoadjuvant chemotherapy for triple-negative breast cancer (TNBC) varies across age groups. We evaluated age-related patterns in immune-related adverse events (irAEs), pembrolizumab exposure, and clinical outcomes in TNBC patients treated with the KEYNOTE-522 regimen.Methods: We retrospectively analyzed TNBC patients treated with neoadjuvant ± adjuvant pembrolizumab from 2020–2025 at a multicenter healthcare network. Patients were stratified by median age (53 years), with a prespecified sensitivity analysis at 65 years. We compared irAE incidence and severity, treatment completion, pathologic complete response (pCR), event-free survival, and overall survival (OS) using Kaplan–Meier analysis and univariable Cox regression.Results: Among 125 patients, 36.8% developed an irAE, and 15.2% experienced grade ≥3 events. Patients <53 years experienced more irAEs (51% vs. 31%; p = 0.03), developed toxicity earlier (mean 5.7 vs. 7.2 cycles), and required more corticosteroid therapy (36% vs. 18%; p = 0.04). This association was consistent in the sensitivity analysis (odds ratio 3.63, 95% confidence interval [CI] 1.43–9.06, p = 0.006). Despite reduced pembrolizumab exposure, pCR was similar across age groups (72% vs. 73%; p = 0.8). Completion of adjuvant pembrolizumab was associated with improved OS overall (hazard ratio 0.17, 95% CI 0.04–0.75), with a trend toward older patients benefiting more.Conclusion: Younger patients experienced more frequent and earlier irAEs leading to treatment discontinuation yet achieved comparable pCR rates. Older patients were more likely to complete the full regimen with a trend toward improved survival with treatment completion. Age-adapted immunotherapy strategies in early-stage TNBC should be explored.